Hemodialysis Recalls: 821 Events Show the Burden Sits in Disposables, Not Machines

Executive Summary

Hemodialysis is a life-sustaining therapy delivered to roughly 4 million people worldwide, and the devices that deliver it generate a substantial and distinctive recall record. Our analysis of the complete FDA device recall and enforcement database for the hemodialysis and peritoneal-dialysis product-code family (regulation 21 CFR 876 — hemodialysis systems and devices, plus related dialysis disposables and concentrates) finds 821 individual recall events:

Although this analysis focuses on dialysis, teams managing renal and pelvic-health portfolios can use this global urology and women's-health device overview to compare neighboring product families and market-entry requirements.

• Only 28 of those events (3.4%) involve the dialysis delivery machine itself; the remaining 793 (96.6%) sit in disposables, access catheters, dialyzers, and dialysate concentrate — a structural pattern that reframes where dialysis recall risk actually lives

• 82 events escalated to FDA Class I, concentrated in hemodialysis catheters (NIE, MSD), high-permeability dialyzers (KDI), and peritoneal administration sets (KDJ), with a single sharp spike of 36 Class I events in 2023

• Implanted hemodialysis catheters (MSD, 270 events) and high-permeability dialyzers (KDI, 215 events) are the two most-recalled codes, followed by dialysate concentrate (KPO, 105) — the same KPO concentrate family at the center of the 2012 GranuFlo / NaturaLyte Class I litigation

• Fresenius Medical Care and Baxter (now Vantive) dominate the firm ranking, with Covidien (Medtronic), Arrow International (Teleflex), and AngioDynamics rounding out the access-catheter segment

• Root causes skew toward component failure, leaks, labeling, breakage, and concentrate-chemistry issues rather than the software-and-alarm profile seen in infusion pumps

For renal-device quality and regulatory teams, the headline is counterintuitive: the recall burden in dialysis is not a machine-reliability problem. It is a consumable, access-device, and chemistry-integrity problem across a vast, frequently replaced installed base.

The Dialysis Device Family

FDA regulates dialysis devices across dozens of product codes under 21 CFR Part 876. The 26 codes with recall activity in this analysis fall into four functional groups:

The delivery-system group — the machines — is the smallest contributor to recall volume despite being the most visible piece of equipment. The disposables and access group is where the action is.

Data Source and Method

• Sources: FDA Medical Device Recall database cross-referenced to the FDA device enforcement report database for Class I / II / III classification

• Analysis sample: 821 recall records tagged to 26 dialysis-related product codes under 21 CFR Part 876; of these, 577 join to a classified enforcement record (82 Class I, 480 Class II, 15 Class III)

• Run date: 2026-06-14

• Method: All counts were computed by MedDeviceGuide from the public FDA recall and enforcement extracts. Records were grouped by functional category. Root-cause keywords were tallied across each record's reason-for-recall text. Delivery-system ("machine") events were isolated as the FKP / FKQ / FII / FIL / KPF / ONW / ODN codes plus analogous single-pass and sealed-system codes; everything else is reported as disposables/accessories/consumables. Firm names are reproduced as recorded by FDA; corporate successors are noted in the text.

The Headline Finding: Machines Rarely Recall; Disposables Do

Splitting the 821 events by functional category produces the analysis's central result:

This does not mean dialysis machines never fail — Fresenius Medical Care's 2008T hemodialysis machine was the subject of a 2023 Class I action over non-dioxin-like polychlorinated biphenyl acids (PCBAs) found in the silicone tubing of the 2008 Series, resolved by switching to platinum-catalyst silicone tubing cleared by FDA in October 2022 (Fresenius Medical Care, 2023). But machine-level events are rare because the installed base is comparatively small, units are serviced rather than replaced, and a machine defect typically affects a defined serial-number range.

The disposable side is the opposite. Catheters, dialyzers, sets, and concentrate are manufactured and shipped in the hundreds of millions of units per year, replaced per treatment, and any lot-level defect multiplies quickly into a recall. Fresenius Medical Care's November 2023 Class I recall of Sanxin single-use heparin syringes — used with the 2008T — covered 12.47 million units over leakage and particulate concerns (ONS/FDA, 2023). A single disposable recall can dwarf an entire year of machine recalls in unit terms.

Recall Volume by Product Code

The product-code ranking makes the disposable concentration explicit:

Access catheters (MSD + NIE + NYU + MPB = 356 events) and dialyzers plus concentrate (KDI + KPO = 320 events) together account for more than four-fifths of all dialysis-family recalls. The single most-recalled machine code, FKP, ranks ninth by volume.

Class I: A Concentrated, Chemically Driven Risk

Of the 577 classified dialysis-family recalls, 82 are Class I — and they cluster in the same access-catheter and dialyzer codes:

The Class I timeline is dominated by a single anomalous year:

The 2023 spike — 36 Class I events in one year — aligns with the Fresenius 2008T machine action, the Sanxin syringe action, and a cluster of hemodialysis-catheter recalls across the access-device segment. It is the most concentrated year of Class I dialysis activity in the enforcement record.

The KPO concentrate code carries particular historical weight: Fresenius Medical Care's GranuFlo and NaturaLyte acid concentrates were the subject of a 2012 Class I recall over alkalosis and cardiac-arrest risk, leading to multidistrict litigation (MDL No. 2428) and a $250 million settlement (FDA, 2012; Kreindler, 2016). That episode is the archetype of why dialysate chemistry integrity is treated as a Class I-level concern.

Root Causes: Components, Leaks, and Chemistry

Tallying reason-for-recall text across the 821 events shows a different failure profile from software-driven device families:

The prominence of component failure, leaks, breakage, and concentrate chemistry reflects the physical and disposable nature of the dominant codes. Catheter hubs crack; dialyzer membranes leak blood across the barrier; concentrate is mixed or labeled incorrectly. These are manufacturing-process and supplier-control problems first, and design problems second — a different quality-system emphasis than a software-heavy device family.

The Firms Behind the Record

The firm ranking maps cleanly onto the product-code structure:

The dialysis market has consolidated sharply, and the recall record reflects it. Fresenius Medical Care absorbed NxStage Medical (home hemodialysis) in February 2019 (Fresenius Medical Care, 2019). Baxter agreed in 2024 to sell its kidney-care segment (branded Vantive) to Carlyle for $3.8 billion, and the transaction closed in January 2026, completing the spinout into a standalone company (Baxter, 2024; Vantive, 2026). A parallel kidney-care joint venture between Medtronic and DaVita created Mozarc Medical in 2022. On the access-catheter side, Covidien's renal business sits inside Medtronic and Arrow's sits inside Teleflex. As with infusion pumps, recall records filed under legacy names (Gambro, NxStage, Covidien, Arrow) should be read as lineage for the current corporate owners.

What This Means for Renal-Device Teams

1. Resource the disposable and access-device quality system, not just the machine. The data shows decisively that recall exposure in dialysis is created at the catheter, dialyzer, set, and concentrate level. Supplier qualification, lot-release testing, and sterility assurance for high-volume consumables are the primary controls.

2. Treat concentrate chemistry as a Class I risk. The GranuFlo / NaturaLyte precedent and the 2023 concentrate actions show that composition and labeling errors in dialysate concentrate escalate quickly.

3. Plan for high-unit-count disposables recalls. The Sanxin syringe action (12.47 million units) illustrates the field-correction scale that a single disposable lot problem can reach.

4. Watch the access-catheter segment. Implanted and triple-lumen hemodialysis catheters (MSD, NIE, NYU) are the largest single source of both total recalls and Class I events in the family.

The dialysis recall record is, in effect, a map of where life-sustaining therapy meets high-volume disposable manufacturing. The machines are reliable and rarely recalled; the consumables that flow through them are where the risk — and the regulatory attention — concentrates.

Data sources: FDA Medical Device Recall database and FDA device enforcement report database; analysis by MedDeviceGuide, run date 2026-06-14. Root-cause themes are derived from FDA reason-for-recall text and are not mutually exclusive. This article is educational and is not regulatory, quality-system, or clinical advice for a specific product.